2022
Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma
Navani V, Ernst M, Wells J, Yuasa T, Takemura K, Donskov F, Basappa N, Schmidt A, Pal S, Meza L, Wood L, Ernst D, Szabados B, Powles T, McKay R, Weickhardt A, Suarez C, Kapoor A, Lee J, Choueiri T, Heng D. Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma. JAMA Network Open 2022, 5: e2216379. PMID: 35687336, PMCID: PMC9187954, DOI: 10.1001/jamanetworkopen.2022.16379.Peer-Reviewed Original ResearchConceptsInternational Metastatic Renal Cell Carcinoma Database ConsortiumMetastatic renal cell carcinomaIO combination therapyInternational Metastatic Renal Cell Carcinoma Database Consortium riskPresence of lung metastasesCombination therapyCytoreductive nephrectomyComplete responseStable diseasePartial responseOverall survivalLung metastasesProgressive diseaseImmuno-oncologyImaging responseDiagnosis of metastatic renal cell carcinomaVascular endothelial growth factor inhibitorsIncreased likelihood of responseMedian overall survivalResponse Evaluation CriteriaGrowth factor inhibitorsMulticenter international cohort studyRenal cell carcinomaLikelihood of responseInternational cohort study
2021
Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma
Meza L, Malhotra J, Favorito C, Pal S. Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma. Future Oncology 2021, 18: 21-33. PMID: 34766841, DOI: 10.2217/fon-2021-0570.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMetastatic renal cell carcinomaMetastatic urothelial carcinomaTargeted therapyTreatment of metastatic RCCMetastatic renal cellNonresponders to monotherapyRenal cell carcinomaIncrease clinical responsesImmunotherapy combinationsMetastatic RCCUrothelial carcinomaClinical responseCell carcinomaProgressive diseaseIO agentsTreatment optionsRenal cellsImmunotherapyQuality of lifeCabozantinibMonotherapyCarcinomaNovel approachesNonrespondersTherapyOutcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
Gan C, Wells J, Schmidt A, Powles T, Tran B, Meza L, Labaki C, Lee J, Wood L, Shapiro J, Ernst D, Kapoor A, Canil C, Yuasa T, McKay R, Beuselinck B, Donskov F, Dudani S, Choueiri T, Heng D. Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Journal Of Clinical Oncology 2021, 39: 4554-4554. DOI: 10.1200/jco.2021.39.15_suppl.4554.Peer-Reviewed Original ResearchInternational mRCC Database ConsortiumMetastatic renal cell carcinomaIpi-nivoOverall survivalCell histologyInternational mRCC Database Consortium criteriaOutcomes of first-lineTreatment durationNon-clear cell histologyPoor-risk diseaseTyrosine kinase inhibitorsRenal cell carcinomaRisk categoriesMedian OSBrain metastasesBone metastasesLiver metastasesPoor riskRisk diseaseCell carcinomaFirst-lineMedian ageProgressive diseaseMedian TDNeutrophil count